THRIVE Intervention for Suicide Crisis

(THRIVE Trial)

Overseen By Anthony R Pisani, PhD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Centerstone Research Institute

Disqualifiers: Acute psychosis, Communication issues

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 4 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 5

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new program called THRIVE, designed to assist individuals in crisis stabilization centers who are at risk for suicide. The researchers aim to determine if THRIVE, a 60-minute, tech-based session, can enhance understanding of their crisis, reduce suicidal thoughts, and improve recovery more effectively than usual care. The trial includes two groups: one receiving THRIVE plus usual care and another receiving only usual care. It seeks participants admitted to a crisis stabilization center, residing in Davidson County, and identified as at increased risk for suicide. As an unphased trial, this study provides a unique opportunity to contribute to innovative approaches in mental health care.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your healthcare provider.

What prior data suggests that the THRIVE intervention is safe for individuals in crisis stabilization centers?

Research has shown that most people find THRIVE easy to handle. In one study, 94% of participants completed the entire THRIVE program, indicating a willingness to continue, which often means the treatment is manageable. No reports of unexpected safety problems with THRIVE have emerged. While more research is needed, these findings suggest THRIVE could be a safe option for those experiencing a suicide crisis. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the THRIVE intervention for suicide crisis because it offers a new approach by integrating a structured crisis intervention method with usual care practices. Unlike traditional treatments, such as medication and therapy, THRIVE is designed to be implemented in community-based crisis stabilization centers, providing immediate support when individuals are at their most vulnerable. This approach may lead to more rapid stabilization and support, potentially reducing the risk of suicide more effectively than existing methods. By offering this enhanced level of care in a community setting, THRIVE could revolutionize how mental health crises are managed, providing timely and tailored support for those in need.

What evidence suggests that the THRIVE intervention is effective for suicide crisis?

Research has shown that the THRIVE program might help people in a suicide crisis by reducing suicidal thoughts and aiding recovery. Earlier studies tested THRIVE with adults who received suicide prevention services, and it showed promise as a follow-up program. In this trial, participants will receive either the THRIVE program alongside usual care or just usual care. The new 60-minute THRIVE session helps individuals understand their crisis and supports their recovery. Although specific data on THRIVE's effect on suicide risk is not yet available, its design and early use suggest it could be a valuable tool in crisis care. ^{1 3 6 7 8}

Who Is on the Research Team?

Jennifer Lockman, PhD

Principal Investigator

Centerstone Research Institute

Are You a Good Fit for This Trial?

This trial is for English-speaking residents of Davidson County who are at increased risk for suicide and have been admitted to a Crisis Stabilization Center. Participants must be able to give informed consent, provide contact information for follow-ups, and discuss their suicidal thoughts or attempts. Those acutely psychotic or unable to communicate with the research team cannot join.

Inclusion Criteria

Medically and clinically cleared by onsite psychiatrist/nurse practitioner

Increased risk for suicide (Patient safety screener-3, Item 2 and/or 3 is 'Yes')

English-speaking

Exclusion Criteria

Individuals unable to communicate with the research team

Individuals who are acutely psychotic

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Intervention

Participants receive the THRIVE intervention, a 60-minute, narrative, technology-based, recovery-oriented intervention tailored for CSC settings

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after the intervention, with surveys administered at baseline, discharge, 1 month, and 3-month follow-up time points

3 months

4 visits (in-person or virtual)

What Are the Treatments Tested in This Trial?

Interventions

• THRIVE
• Usual Care

Trial Overview The study tests THRIVE, a new 60-minute recovery-oriented intervention using narrative and technology, against usual care in Crisis Stabilization Centers. It aims to see if THRIVE can better help individuals understand their suicide crisis, reduce suicidal thoughts, and support recovery.

How Is the Trial Designed?

Group I: Experimental: THRIVE + Usual Care Experimental Treatment 2 Interventions

Individuals presenting to a community-based crisis stabilization center who are age 18-plus and screen positive for suicide risk

Group II: Usual Care Active Control 1 Intervention

Individuals presenting to a community-based crisis stabilization center who are age 18-plus and screen positive for suicide risk

THRIVE is already approved in European Union, United States, Canada, Switzerland for the following indications:

Approved in European Union as Lynparza for:

• Ovarian cancer
• Breast cancer
• Pancreatic cancer
• Prostate cancer

Approved in United States as Lynparza for:

• Ovarian, fallopian tube, and primary peritoneal cancer
• Breast cancer
• Prostate cancer
• Pancreatic cancer

Approved in Canada as Lynparza for:

• Ovarian cancer
• Breast cancer
• Pancreatic cancer
• Prostate cancer

Approved in Switzerland as Lynparza for:

• Ovarian cancer
• Breast cancer
• Prostate cancer

Who Is Running the Clinical Trial?

Centerstone Research Institute

Lead Sponsor

Trials

4

Recruited

1,700+

University of Rochester

Collaborator

Trials

883

Recruited

555,000+

Published Research Related to This Trial

In a post-hoc analysis of 53 patients with major depressive disorder and suicidal ideation, intranasal esketamine showed a significant improvement in depression scores compared to placebo, with a mean difference of -3.8 on the MADRS scale by Day 2.

The safety profile of intranasal esketamine in the Asian subgroup was consistent with the overall ASPIRE I cohort, indicating no unexpected safety concerns.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and safety of esketamine nasal spray in addition to standard of care in patients with major depressive disorder who have active suicidal ideation with intent: A subgroup analysis of the Asian cohort of ASPIRE I (a randomized, double-blind, placebo-controlled study). Hong, JP., Malek, AZA., Li, CT., et al.[2023]

The STAR*D study successfully implemented NIMH guidelines to manage suicidal risk in a large clinical trial involving an anticipated 4000 participants, focusing on treatment-resistant depression.

Innovative methods, such as an interactive voice response system, were utilized to enhance safety monitoring and ensure timely alerts for clinicians and safety officers regarding suicidal subjects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines. Nierenberg, AA., Trivedi, MH., Ritz, L., et al.[2022]

In a study involving 16 recent suicide attempters, a single intravenous dose of ketamine (0.5 mg/kg) led to rapid and significant reductions in suicidal thoughts within 24 hours, with effects lasting up to 6 months post-infusion.

The results indicate that ketamine is a safe and effective treatment for reducing suicidality in high-risk patients, suggesting it could be integrated into existing healthcare settings for those in acute psychiatric care.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A Pilot Study of Ketamine Infusion after Suicide Attempt: New Frontiers in Treating Acute Suicidality in a Real-World Medical Setting. Shivanekar, S., Gopalan, P., Pizon, A., et al.[2023]

Citations

1. afsp.org afsp.org/grant/thrive-pilot-study-of-a-brief-recovery-focused-intervention-for-crisis

THRIVE: Pilot Study of a Brief, Recovery-Focused ... THRIVE may help people make meaning of their suicide crisis, reduce suicidal ideation, and increase their recovery compared to usual care. If effective, THRIVE ...

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12272113/

Study protocol for a randomized controlled effectiveness ... THRIVE was previously piloted as a crisis follow-up program in five adult cohorts receiving suicide prevention services through SAMHSA grants. In this protocol, ...

3. pubmed.ncbi.nlm.nih.gov pubmed.ncbi.nlm.nih.gov/40401321/

THRIVE: Feasibility, Acceptability, and Social Validity of a ... The purpose of this study was to establish the feasibility, acceptability, appropriateness, and social validity of a novel, ultra-brief, 60-min psychotherapy ...

4. suicideinfo.ca suicideinfo.ca/wp-content/uploads/2025/05/Suicide-Life-Threat-Behav-2025-Lockman-THRIVE-Feasibility-Acceptability-and-Social-Validity-of-a-Brief.pdf

THRIVE: Feasibility, Acceptability, and Social Validity of a ... To date, there have been no empirical studies or clinical trials examining suicide risk outcomes among CSC guests or examining CSC guest ...

5. sciencedirect.com sciencedirect.com/science/article/pii/S016517812400088X

The effectiveness of a suicide prevention program in ... The suicide rate in the intervention area decreased by 25% following the intervention. Implementation of the LinkPC-PH intervention was associated with ...

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC12096272/

THRIVE: Feasibility, Acceptability, and Social Validity of a ... Further, 94% of guests completed all phases of THRIVE, demonstrating clinical readiness to work on suicide recovery beyond physical safety or stabilization from ...

7. withpower.com withpower.com/trial/phase-suicide-5-2022-d58a8

THRIVE Intervention for Suicide Crisis · Info for Participants The safety of treatments like esketamine, which is used for major depression with suicidal thoughts, has been studied and found to have no unexpected safety ...

8. publications.aap.org publications.aap.org/pediatrics/article/153/3/e2023061881/196630/Brief-Interventions-for-Suicidal-Youths-in-Medical

Brief Interventions for Suicidal Youths in Medical Settings Brief suicide interventions for youth in outpatient medical settings can increase identification of risk, increase access to behavioral health services,